Background: Nephrogenic systemic fibrosis is a fibrosing disorder associated with exposure to gadolinium-based contrast agents in people with severely compromised renal function.

Objective: The purpose of this study was to determine the reported number of cases of nephrogenic systemic fibrosis in children using three distinct publicly available data sources.

Materials And Methods: We conducted systematic searches of the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS), the International Center for Nephrogenic Systemic Fibrosis Research (ICNSFR) registry and published literature from January 1997 through September 2012. We contacted authors of individual published cases to obtain follow-up data. Data sets were cross-referenced to eliminate duplicate reporting.

Results: We identified 23 children with nephrogenic systemic fibrosis. Seventeen had documented exposure to gadolinium-based contrast agents. Six children had been reported in both the FAERS and the literature, four in the FAERS and the ICNSFR registry and five in all three data sources.

Conclusion: Nephrogenic systemic fibrosis has been rarely reported in children. Although rules related to confidentiality limit the ability to reconcile reports, active pharmaco-vigilance using RADAR (Research on Adverse Drug events And Reports) methodology helped in establishing the number of individual pediatric cases within the three major data sources.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946726PMC
http://dx.doi.org/10.1007/s00247-013-2795-xDOI Listing

Publication Analysis

Top Keywords

nephrogenic systemic
24
systemic fibrosis
24
fibrosis rarely
8
rarely reported
8
exposure gadolinium-based
8
gadolinium-based contrast
8
contrast agents
8
icnsfr registry
8
systemic
6
fibrosis
6

Similar Publications

Adverse reactions to radiological contrast media: Prevention and treatment.

Radiologia (Engl Ed)

October 2024

Servicio de Alergia, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IIS-P), Madrid, Spain. Electronic address:

Radiological contrast media, both iodinated and gadolinium-based, can lead to adverse reactions. Type A reactions are related to the pharmacological characteristics of the contrast, including side, secondary and toxic effects. Post-contrast acute kidney injury is the most frequent adverse reaction to iodinated contrast media.

View Article and Find Full Text PDF

Magnetic resonance imaging (MRI) remains a cornerstone of diagnostic imaging, offering unparalleled insights into anatomical structures and pathological conditions. Gadolinium-based contrast agents have long been the standard in MRI enhancement, yet concerns over nephrogenic systemic fibrosis have spurred interest in metal-free alternatives. Nitroxide radical-based MRI contrast agents (NO-CAs) have emerged as promising candidates, leveraging their biocompatibility and imaging capabilities.

View Article and Find Full Text PDF

Background: Calciphylaxis is a rare and life-threatening condition characterized by cutaneous necrosis resulting from vessel calcification and thrombosis. Commonly associated with end-stage renal disease and hyperparathyroidism, calciphylaxis presents as retiform purpura evolving into necrotic eschars.

Case Report: This report details an atypical case of non-nephrogenic unilateral bullous calciphylaxis in a 71-year-old female, emphasizing the importance of considering calciphylaxis in the differential diagnosis of bullous disorders.

View Article and Find Full Text PDF

ASNR Statement on Gadolinium-Based Contrast Agent Use in Patients with Chronic Kidney Disease.

AJNR Am J Neuroradiol

September 2024

From the Department of Radiology, Mayo Clinic, Rochester MN, USA (K.M.W), Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA (D.J.), Department of Radiology, Loyola University Medical Center, Maywood, IL, USA (A.W.K), Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA (D.S.L.), Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA (A.M.S., C.S), Department of Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA (N.Y.), and Department of Radiology, Providence Little Company of Mary Medical Center, Torrance, CA, USA (J.E.J.).

Article Synopsis
  • Since 2006, neuroradiologists have restricted the use of gadolinium-based contrast agents (GBCAs) in patients with chronic kidney disease (CKD) to prevent nephrogenic systemic fibrosis (NSF), significantly reducing its occurrence.
  • In 2023-2024, the American Society of Neuroradiology reviewed recent research on GBCA safety to update guidelines for MRI contrast use in CKD patients.
  • The ASNR now recommends that Group II GBCAs can be safely used in CKD patients when necessary for diagnosis, and additional safety measures like checking renal function may be relaxed.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!